Implanet Announces Publication of a Cost Effectiveness Study of JAZZ™ Band in Adolescent Idiopathic Scoliosis
BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:
IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specialized in vertebral and knee-surgery implants, today announces publication of a retrospective cost effectiveness study documenting the potential economic benefit of the JAZZ™ Band in scoliosis surgery.
Ludovic Lastennet, CEO of Implanet, says: “The clinical results of sublaminar band technology used in a hybrid construct in the treatment of Adolescent Idiopathic Scoliosis (AIS), are well documented. This study is the first of its kind, documenting the incremental profit potential of JAZZ when used in AIS treatment. The dramatic benefits highlighted in this research illustrate Implanet’s continued commitment to delivering technological advancements for improved patient outcomes, enhancing procedural safety for the clinical team, and making a positive economic impact on the hospital’s bottom line. ”
Health Advances analyzed key hospital cost metrics for two implant configurations in the surgical treatment of AIS: all pedicle screw constructs and hybrid constructs consisting of pedicle screws and sublaminar bands. The following benefits were demonstrated with JAZZ Band hybrid constructs:
- Reduced number of implants per case
- Decreased procedure length
- Reduced blood loss
- Reduced duration of hospital stay
